Protalix Biotherapeutics For a Monster 180% Win!

February 11, 2017: Sell Protalix Biotherapeutics for a monster 180% win! This is our biggest winner to date. Long upper shadow and Inverted Hammer candlestick are usually good take profit signals. Congratulations if you made money on the trade.

December 27, 2016: Protalix Biotherapeutics announced today the confirmation of the recent letter of intent to purchase alfataliglicerase to treat Gaucher patients in Brazil by the Brazilian Ministry of Health. The Brazilian Ministry’s order consists of a number of shipments during 2017 for a total of approximately $24.3 million. Shipments are to start in mid-2017 and continue through the end of the year, in increasing volumes. The size of the final shipment of this order represents annual revenues of approximately $42 million.

Gaucher disease is a rare lysosomal storage disorder. Alfataliglicerase is a plant cell-expressed form of the glucocerebrosidase enzyme that was approved by the Brazilian National Health Surveillance Agency in March 2013 for the long-term treatment of adults with Type I Gaucher disease and in November 2016 for the long-term treatment of children four years of age and above with Type I Gaucher disease.

The Company owns all rights to alfataliglicerase in Brazil.

December 14, 2016: Protalix Biotherapeutics announced today that the Company received a letter from Fundao Oswaldo Cruz (Fiocruz), an arm of the Brazilian Ministry of Health (the Brazilian Ministry), detailing intended purchases by the Brazilian Ministry of alfataliglicerase to treat Gaucher patients in Brazil. The letter requests three shipments of alfataliglicerase; the first shipment to be made in the middle of 2017, and the last at the end of 2017. The Company estimates total revenues from these shipments to be approximately $24 million in aggregate.

Gaucher disease is a rare lysosomal storage disorder. Alfataliglicerase is a plant cell-expressed form of the glucocerebrosidase enzyme that was approved by the Brazilian National Health Surveillance Agency in March 2013 for the long-term treatment of adults with Type I Gaucher disease and in November 2016 for the long-term treatment of children four years of age and above with Type I Gaucher disease.The Company owns all rights to alfataliglicerase in Brazil.

November 29, 2016: The price target on Protalix Biotherapeutics was raised to $4 from $3.50 at H.C. Wainwright/Rodman & Renshaw. H.C. Wainwright also reiterates their Buy rating on Protalix Biotherapeutics.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner.

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised: None

Initiates: None

Cuts: None

Overnight Headlines By Ticker:

PLX Protalix Biotherapeutics Inc

12/27 07:30 Receives confirmation of order for over $24M of alfataliglicerase to treat gaucher patients in Brazil

PTLA Portola Pharmaceuticals

12/27 07:49 Price Target raised to $29 from $20 at Credit Suisse, reiterates Neutral rating

SGEN Seattle Genetics

12/27 08:00 Announces clinical hold on several Phase 1 trials of Vadastuximab Talirine after deaths [SELL NO LONGER COVERING]

12/27 07:55 Trading halted; news pending; to resume trading at 08:30ET

Stock Market Forecast For Week of December 19 2016

A weekly Saturday night financial show that attempts to predict market direction for the week ahead by looking at a variety of technical and fundamental indicators. This week’s show includes commentary on the Fed’s first and only rate hike in 2016, Eli Lilly’s long-acting Basal Insulin that’s now available in the US, takeover rumors circulating about Qorvo, Protalix Biotherapeutics $24 million order to treat Gaucher patients in Brazil, the FDA approval of Vericel’s Maci for the repair of cartilage defects of the knee, Silicon Motion’s supplying of SSD solutions to the Alibaba Group, and more.